The standard lipid panel that your doctor orders – total cholesterol, LDL-C, HDL-C, triglycerides, and sometimes VLDL – was designed in the Framingham era to detect people at immediate risk of cardiovascular events. It was optimized for a specific clinical question: is this person about to have a heart attack? That question is not the same as the prevention question: is this person on a trajectory toward cardiovascular disease in 20 years?
The most common misunderstanding is what LDL-C actually measures. LDL-C estimates the mass of cholesterol carried inside LDL particles. It does not count the particles themselves. ApoB – apolipoprotein B – counts every atherogenic particle in circulation, including LDL, VLDL, IDL, and Lp(a), because each of these particles carries exactly one ApoB molecule [1]. The distinction matters because the particles cause plaque, not the cholesterol inside them.
Think of it this way: LDL-C is like measuring the total weight of cars on a highway. ApoB is like counting the cars themselves. If car manufacturers start making lighter cars, the total weight goes down while the number of cars stays the same – and it is the cars, not their weight, that determine traffic and collision risk. The cholesterol inside a lipoprotein particle is cargo. The particle density determines how many get trapped in the arterial wall.
Two people can have identical LDL-C levels while one has twice as many atherogenic particles. This discordance occurs because LDL particles vary in size and cholesterol content. People with predominantly small, dense LDL particles have “normal” LDL-C (because each particle carries less cholesterol) but high ApoB – and therefore higher cardiovascular risk that the standard panel misses entirely [2]. The prevalence of this discordance is approximately 15-20% in the general population, and higher in people with insulin resistance, type 2 diabetes, and elevated triglycerides.
The test your doctor orders was designed in a clinical context where the goal was to identify people who needed statin therapy to prevent near-term events. For that purpose, LDL-C works reasonably well at the population level. But if you are 45 years old, asymptomatic, and paying for prevention, LDL-C leaves important information on the table.
What should a prevention-focused lipid panel include? The Bettering Me minimum is: ApoB, Lp(a) (checked once), non-HDL cholesterol, triglycerides, and HDL-C. Non-HDL cholesterol (total cholesterol minus HDL-C) is a reasonable proxy when ApoB is unavailable – it captures all atherogenic lipoproteins and correlates well with ApoB at the population level [3]. But it is still a proxy. ApoB is the direct measure.
Lipoprotein(a) – Lp(a) – should be checked once in a lifetime. It is 80-90% genetically determined and does not respond significantly to lifestyle intervention [4]. A single high reading (above 50 mg/dL or above 125 nmol/L, depending on the assay) means you need aggressive ApoB management because your baseline atherogenic particle production is genetically elevated. The European Atherosclerosis Society recommends that everyone be tested for Lp(a) at least once [4]. A high reading does not mean you are doomed – it means you should target an ApoB below 70 mg/dL instead of below 100 mg/dL.
What about optimal ApoB targets? For primary prevention in a 45-year-old with no known cardiovascular disease, an ApoB below 100 mg/dL is the minimum acceptable. Below 90 mg/dL is optimal. Below 80 mg/dL is aggressive [3]. These targets are lower than what most clinical guidelines recommend because the guidelines are designed for population-wide risk management, not individual optimization. If you have Lp(a) above 50 mg/dL, traditional risk factors (hypertension, smoking, diabetes), or a family history of premature cardiovascular disease, your target should be below 70 mg/dL.
Counterpoint: isn’t LDL-C good enough for most people? At the population level, yes – LDL-C correlates with cardiovascular risk well enough that guidelines use it. But you are not a population. You are an individual. If you are in the 15-20% of people whose risk is discordant with their LDL-C, the standard panel is misleading you. The cost of checking ApoB is approximately $30-50 out of pocket if your insurance does not cover it. A standard lipid panel costs $50-100. The incremental cost of knowing your true risk is approximately $30. Compared to what you spend on supplements, gym memberships, and organic food, that is the cheapest prevention dollar you can spend.
The standard panel is not useless. It is incomplete for the prevention context. Knowing your LDL-C without knowing your ApoB is like knowing your speed without knowing whether you are driving on a straight road or a winding mountain pass. The speed is useful. The context determines the risk. Pay for the context.
Practical guidance for your next lab visit. When your doctor orders “lipid panel,” you get total cholesterol, LDL-C, HDL-C, triglycerides, and VLDL. To get ApoB, ask for “apolipoprotein B” – CPT code 82172. To get Lp(a), ask for “lipoprotein (a)” – CPT code 83695. Some labs bundle these as an “advanced lipid panel” or “cardiovascular risk panel.” Cost: approximately $50-100 out of pocket for the add-ons if insurance declines. Most major labs offer cash-pay direct ordering. If ApoB is not available, non-HDL cholesterol (total minus HDL) is an acceptable surrogate – and most standard panels already report non-HDL-C. If non-HDL-C is above 130 mg/dL, you can infer your ApoB is likely above 100 mg/dL, and you should push for the direct ApoB measurement.
Disclaimer: This post is for inspiration and education, not medical advice. Everyone’s body is different, so please check with your doctor before changing your diet, exercise, or lifestyle routine. By using these tips, you agree to do so at your own risk.
References
[1] Sniderman AD, et al. "A meta-analysis of LDL-C, non-HDL-C, and ApoB as markers of cardiovascular risk." *Circ Cardiovasc Qual Outcomes*. 2011;4(3):337-345.. DOI: https://doi.org/10.1161/CIRCOUTCOMES.110.959247
[2] Otvos JD, et al. "Clinical implications of discordance between LDL-C and particle number." *J Clin Lipidol*. 2011;5(2):105-113.. DOI: https://doi.org/10.1016/j.jacl.2011.02.001
[3] Sniderman AD, et al. "Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review." *JAMA Cardiology*. 2019;4(12):1287-1295.. DOI: https://doi.org/10.1001/jamacardio.2019.3780
[4] Kronenberg F. "Human Genetics and the Causal Role of Lipoprotein(a)." *Cardiovasc Drugs Ther*. 2016;30(1):87-100.. DOI: https://doi.org/10.1007/s10557-016-6648-3